ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 40 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $4,850,000 | +13.9% | 371,617 | 0.0% | 1.25% | +2.3% |
| Q2 2018 | $4,259,000 | -45.6% | 371,617 | -49.2% | 1.22% | +48.9% |
| Q1 2018 | $7,835,000 | +43.1% | 731,510 | -14.3% | 0.82% | +166.0% |
| Q4 2017 | $5,476,000 | -17.7% | 853,885 | -0.6% | 0.31% | +24.6% |
| Q3 2017 | $6,650,000 | +17.6% | 859,392 | -36.8% | 0.25% | +64.2% |
| Q2 2017 | $5,655,000 | -18.5% | 1,360,647 | 0.0% | 0.15% | -30.1% |
| Q1 2017 | $6,940,000 | +160.7% | 1,360,647 | +107.0% | 0.22% | +166.7% |
| Q4 2016 | $2,662,000 | -47.7% | 657,258 | -9.0% | 0.08% | -57.8% |
| Q3 2016 | $5,092,000 | -20.3% | 722,233 | -7.8% | 0.19% | -56.4% |
| Q2 2016 | $6,387,000 | +0.3% | 783,645 | 0.0% | 0.44% | +12.5% |
| Q1 2016 | $6,371,000 | -20.6% | 783,645 | +17.7% | 0.39% | -13.3% |
| Q4 2015 | $8,027,000 | +91.6% | 665,566 | +90.2% | 0.45% | +213.2% |
| Q3 2015 | $4,190,000 | -34.7% | 350,000 | 0.0% | 0.14% | +48.5% |
| Q2 2015 | $6,415,000 | – | 350,000 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Syncona Portfolio Ltd | 1,377,294 | $1,501,250 | 2.44% |
| NEA Management Company, LLC | 17,079,779 | $18,616,958 | 1.29% |
| Endurant Capital Management LP | 1,660,835 | $1,810,310 | 0.93% |
| Matrix Capital Management Company, LP | 38,974,185 | $42,481,862 | 0.58% |
| Long Focus Capital Management, LLC | 5,435,439 | $5,924,629 | 0.34% |
| PFM Health Sciences, LP | 5,992,571 | $6,531,902 | 0.29% |
| Key Client Fiduciary Advisors, LLC | 321,155 | $350,059 | 0.22% |
| DAFNA Capital Management LLC | 351,064 | $382,660 | 0.12% |
| Rock Springs Capital Management LP | 2,787,845 | $3,038,751 | 0.07% |
| Baker Brothers Advisors | 9,830,877 | $10,715,656 | 0.06% |